Chelsea Therapeutics (CHTP) tumbles 23% after the FDA asks for an additional study to show the durability of the company's Northera drug over a 2-3 month period. The request comes despite an agency panel recommending approval of Northera, which is designed to help stop patients with conditions like Parkinson's disease from tumbling.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/